STAAR Surgical (Nasdaq:STAA) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

STAA Panoramica delle azioni

STAAR Surgical Company, insieme alle sue consociate, progetta, sviluppa, produce, commercializza e vende lenti impiantabili per l'occhio e i relativi sistemi di applicazione delle lenti nell'occhio.

Informazioni sull'azienda

STAA analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	2/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 42% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 37.54% all'anno

Analisi del rischio

I margini di profitto (5%) sono inferiori rispetto allo scorso anno (8.5%)

STAAR Surgical Company Concorrenti

Meridian Bioscience

NasdaqGS:VIVO

US$1.5b

UFP Technologies

NasdaqCM:UFPT

US$2.5b

Haemonetics

NYSE:HAE

US$3.9b

Avanos Medical

NYSE:AVNS

US$1.0b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per STAAR Surgical
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$38.29
Massimo di 52 settimane	US$52.68
Minimo di 52 settimane	US$26.66
Beta	0.60
1Variazione di 1 mese	-9.91%
Variazione a 3 mesi	-9.93%
Variazione di 1 anno	-9.29%
3Variazione a 3 anni	-71.30%
Variazione a 5 anni	28.88%
Variazione dall'IPO	61.22%

Notizie e aggiornamenti recenti

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10

Recent updates

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

Aug 05

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Jul 12

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

May 27

Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

Apr 26

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

Apr 05

STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Mar 25

STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade

Mar 13

STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Mar 07

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Jan 31

With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Jan 05

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Nov 30

Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Nov 12

Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

Oct 25

Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Aug 24

Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Jul 02

Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Jun 17

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

May 13

A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Mar 26

STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Mar 12

Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Feb 13

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Jan 28

Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Dec 15

The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising

Dec 01

What Is STAAR Surgical Company's (NASDAQ:STAA) Share Price Doing?

Oct 26

Keep Adding To STAAR Surgical Longs, Buy Thesis Remains

Sep 20

Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?

Sep 05

STAAR Surgical Company (NASDAQ:STAA) Shares Could Be 24% Above Their Intrinsic Value Estimate

Aug 21

STAAR Surgical rises 15% on Q2 result beat

Aug 11

Should You Think About Buying STAAR Surgical Company (NASDAQ:STAA) Now?

Jul 20

STAAR Surgical: Hard Data Approach Justifies Long-Only Portfolio Allocation

Jul 05

Rendimenti per gli azionisti

	STAA	US Medical Equipment	US Mercato
7D	-0.6%	3.9%	4.9%
1Y	-9.3%	11.2%	25.6%

Ritorno vs Industria: STAA ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento 11.2 % nell'ultimo anno.

Rendimento vs Mercato: STAA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is STAA's price volatile compared to industry and market?
STAA volatility
STAA Average Weekly Movement	8.0%
Medical Equipment Industry Average Movement	8.3%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: STAA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di STAA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1982	1,057	Tom Frinzi	www.staar.com

STAAR Surgical Company, insieme alle sue consociate, progetta, sviluppa, produce, commercializza e vende lenti impiantabili per l'occhio e i relativi sistemi di applicazione per il rilascio delle lenti nell'occhio. L'azienda fornisce una famiglia di lenti impiantabili Collamer (ICL) per il trattamento di disturbi visivi quali miopia, ipermetropia, astigmatismo e presbiopia. L'azienda commercializza i propri prodotti a fornitori di servizi sanitari, tra cui chirurghi oftalmici, centri oculistici e chirurgici, ospedali, strutture governative e distributori, e i prodotti sono utilizzati principalmente da oftalmologi.

STAAR Surgical Company Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di STAAR Surgical con la sua capitalizzazione di mercato?
STAA statistiche fondamentali
Capitalizzazione di mercato	US$1.86b
Guadagni(TTM)	US$16.61m
Ricavi(TTM)	US$332.94m

113.3x

Rapporto P/E

5.7x

Rapporto P/S

STAA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
STAA Conto economico (TTM)
Ricavi	US$332.94m
Costo del fatturato	US$69.13m
Profitto lordo	US$263.81m
Altre spese	US$247.20m
Guadagni	US$16.61m

Ultimi guadagni dichiarati

Jun 28, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.34
Margine lordo	79.24%
Margine di profitto netto	4.99%
Rapporto debito/patrimonio netto	0%

Come si è comportato STAA nel lungo periodo?

Vedi performance storica e confronto

STAA Panoramica delle azioni

Premi

Analisi del rischio

STAAR Surgical Company Concorrenti

NasdaqGS:VIVO

US$1.5b

NasdaqCM:UFPT

US$2.5b

NYSE:HAE

US$3.9b

NYSE:AVNS

US$1.0b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

STAAR Surgical Company Revises Earnings Guidance for the Fiscal Year 2024

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

STAAR Surgical Company to Report Q2, 2024 Results on Aug 07, 2024

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Recent updates

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

STAAR Surgical Company Revises Earnings Guidance for the Fiscal Year 2024

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

STAAR Surgical Company to Report Q2, 2024 Results on Aug 07, 2024

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Consensus EPS estimates fall from profit to US$0.008 loss

STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

STAAR Surgical Company, Annual General Meeting, Jun 20, 2024

Price target increased by 7.1% to US$46.81

Price target increased by 7.2% to US$43.81

Consensus EPS estimates increase by 153%

STAAR Surgical Company to Report Q1, 2024 Results on May 08, 2024

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024

STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024

STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Now 20% overvalued after recent price rise

STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade

STAAR Surgical Company Announces Board Changes

STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Consensus EPS estimates fall by 97%

STAAR Surgical Company Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS exceeds analyst expectations

STAAR Surgical Company to Report Q4, 2023 Results on Feb 26, 2024

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Broadwood Partners Engages in Discussions with STAAR Surgical

Staar Surgical Company Provides Sales Guidance for the Fiscal 2024

With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Now 22% undervalued after recent price drop

STAAR Surgical Company Announces Board Changes

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Now 24% undervalued after recent price drop

Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Now 21% undervalued after recent price drop

New major risk - Earnings quality

Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

STAAR Surgical Company to Report Q3, 2023 Results on Nov 01, 2023

Price target decreased by 7.4% to US$52.38

Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Consensus EPS estimates fall by 51%

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS misses analyst expectations

Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Staar Surgical Company Announces Sales Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Chief Technology Officer recently sold US$51k worth of stock

Chief Financial Officer exercised options to buy US$106k worth of stock.

STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Full year 2022 earnings released: EPS: US$0.81 (vs US$0.52 in FY 2021)

Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

STAAR Surgical Company to Report Q4, 2022 Results on Feb 22, 2023